Cardiometabolic Risk Effects of Short-term Cessation of Neurostimulation Therapy

Who May Qualify: - English-speaking adults (18+ years) who have met surgical efficacy criteria with HGNS, as defined by at least a 50% reduction in apnea-hypopnea index (AHI) to \<20 (with hypopneas defined by 4% oxyhemoglobin desaturations) - Have been using HGNS therapy for at least 3 months and used HGNS for \>20 hours/week during the past 4 weeks - Were not using any OSA therapy for at least one month prior to HGNS activation or have had a one-month period of untreated OSA after HGNS activation Who Should NOT Join This Trial: - Chronic use of opiate medications, illicit drugs, or alcohol dependency - Women who are pregnant or planning to become pregnant - Shift workers, heavy machinery operators, or commercial drivers - History of severe excessive daytime sleepiness (Epworth Sleepiness Scale score \>16 at time of screening or prior to HGNS), motor vehicle accidents or near-miss incidents due to drowsy driving within the year prior to enrollment - Significant cardiopulmonary (such as home oxygen requirement), liver, renal, or oncologic disease; neurodegenerative disease; active or recent history of an eating disorder (within the last 5 years) - Inability to provide willing to sign a consent form Always talk to your doctor about whether this trial is right for you.